The total return over the past 12 months is -91.38% vs. +16.94% for the S&P 500. So far it's up -95.81% this year. Includes price appreciation + reinvested dividends.
| Category | 1Y (TTM) | 3Y | 5Y | 10Y | 15Y | 20Y |
|---|---|---|---|---|---|---|
| Price CAGR | (91.38%) | (50.66%) | (72.96%) | N/A | N/A | N/A |
| Total Return CAGR | (91.38%) | (50.66%) | (72.96%) | N/A | N/A | N/A |
| Revenue CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Net Income CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| EPS CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Free Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Operating Cash Flow CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
| Dividends CAGR | N/A | N/A | N/A | N/A | N/A | N/A |
Visualize historical growth rates over rolling horizons. Use the dropdown to select different metric vectors.
Quince Therapeutics, Inc. (QNCX)
| Year | Start price | End price | QNCX Return | SPY Return | Outperformance |
|---|---|---|---|---|---|
| 2026(YTD) | $670.00 | $28.10 | (95.81%) | +14.51% | (110.32%) |
| 2025 | $374.00 | $670.00 | +79.14% | +17.72% | +61.42% |
| 2024 | $210.00 | $374.00 | +78.10% | +24.89% | +53.21% |
| 2023 | $127.40 | $210.00 | +64.84% | +26.19% | +38.65% |
| 2022 | $2,524.00 | $127.40 | (94.95%) | (18.17%) | (76.78%) |
| 2021 | $5,556.00 | $2,524.00 | (54.57%) | +28.74% | (83.31%) |
| 2020 | $11,228.00 | $5,556.00 | (50.52%) | +18.37% | (68.89%) |
Start and end prices are split-adjusted closing prices. Total return includes reinvested dividends, so it can differ from the price change.
